Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAMBIA: Quantifying Ocular Surface Aberrations After Tear Film Interventions
NCT06966349Phase 4Completed
- Sponsor
- University of Waterloo
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of propylene glycol-hydroxypropyl guar nanoemulsion (2 arms), sponsored by University of Waterloo. Primary endpoints: Change in higher order aberrations with an eye drop at 60 minutes, Change in higher order aberrations with senofilcon A at 6 hours and 1 more. Started Jun 2025; status: completed.
02
Drugs
propylene glycol-hydroxypropyl guar nanoemulsion
Beyond the preview
Go deeper on NCT06966349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966349.